CK Life Sciences International Holdings (HKSE:00775) Total Liabilities : HK$7,058 Mil (As of Dec. 2023)

View and export this data going back to 2002. Start your Free Trial

What is CK Life Sciences International Holdings Total Liabilities?

CK Life Sciences International Holdings's Total Liabilities for the quarter that ended in Dec. 2023 was HK$7,058 Mil.

CK Life Sciences International Holdings's quarterly Total Liabilities declined from Dec. 2022 (HK$7,111.31 Mil) to Jun. 2023 (HK$6,881.92 Mil) but then increased from Jun. 2023 (HK$6,881.92 Mil) to Dec. 2023 (HK$7,058.16 Mil).

CK Life Sciences International Holdings's annual Total Liabilities declined from Dec. 2021 (HK$7,230.17 Mil) to Dec. 2022 (HK$7,111.31 Mil) and declined from Dec. 2022 (HK$7,111.31 Mil) to Dec. 2023 (HK$7,058.16 Mil).

CK Life Sciences International Holdings Total Liabilities Historical Data

The historical data trend for CK Life Sciences International Holdings's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CK Life Sciences International Holdings Total Liabilities Chart

CK Life Sciences International Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

6,539.84

7,259.21

7,230.17

7,111.31

7,058.16

CK Life Sciences International Holdings Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Liabilities	Get a 7-Day Free Trial															7,230.17	7,098.14	7,111.31	6,881.92	7,058.16

CK Life Sciences International Holdings Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

CK Life Sciences International Holdings's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2100.561	+	(4709.328	+	238.567
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	9.701)
	=	7,058

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	11247.41	-	4189.253
	=	7,058

CK Life Sciences International Holdings's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2100.561	+	(4709.328	+	238.567
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	9.701)
	=	7,058

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	11247.41	-	4189.253
	=	7,058

CK Life Sciences International Holdings Total Liabilities Related Terms

Thank you for viewing the detailed overview of CK Life Sciences International Holdings's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

CK Life Sciences International Holdings (HKSE:00775) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CK Life Sciences International Holdings Inc (HKSE:00775) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

LSI:Germany

Address

2 Dai Fu Street, Tai Po Industrial Estate, Tai Po, Hong Kong, HKG

Website

https://www.ck-lifesciences.com

CK Life Sciences International Holdings Inc is a biotechnology company engaged in the research & development, commercialization, and sale of health and agricultural-related products. Products developed by CK Life Sciences are categorized into the areas of human health and environmental sustainability. The company operates three core businesses, including agriculture, nutraceutical, and pharmaceutical. Its overall product portfolio involves a presence that spans North America and the Asia Pacific. The company uses mergers and acquisitions when it identifies attractive market opportunities.

CK Life Sciences International Holdings (HKSE:00775) Headlines

No Headlines